Free Trial
ASX:NTI

Neurotech International (NTI) Stock Price, News & Analysis

Neurotech International logo

About Neurotech International Stock (ASX:NTI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$45.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its products includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. Neurotech International Limited was incorporated in 2016 and is based in Nedlands, Australia.

Receive NTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurotech International and its competitors with MarketBeat's FREE daily newsletter.

NTI Stock News Headlines

Your trading day could end at 11 AM
What do you usually do between 9:35 AM and 11:00 AM? Catch up on emails? Attend a meeting? Maybe grab a coffee? For me, it's become the most important part of my trading day. 85 minutes. That's usually all it takes. Set up at 9:35 AM… Check back at 11:00 AM. And when things work out, there's an extra $100 to $150 in my account… on a $1000 starting stake. Sounds too simple, doesn't it?
Neurotech Director Increases Shareholding in Company
Neurotech International’s AGM Success and Trial Progress
Neurotech’s NTI164 Shows Promise in Neurological Treatment
Neurotech International Appoints New CEO to Drive Growth
See More Headlines

NTI Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotech International investors own include Standard Chartered (SCBFY), Advocate Rising Rate Hedge ETF (RRH), Defiance Next Gen H2 ETF (HDRO) and Cleveland-Cliffs (CLF).

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Petroleum And Natural Gas
CIK
N/A
Fax
N/A
Employees
7,134
Year Founded
N/A

Profitability

Net Income
$-5,070,000.00
Net Margins
15,972.18%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.18 million
Book Value
A$0.01 per share

Miscellaneous

Outstanding Shares
1,030,000,000
Free Float
N/A
Market Cap
$45.85 million
Optionable
Not Optionable
Beta
1.46
10 Best Stocks to Own in 2025 Cover

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (ASX:NTI) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners